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Background: Currently, assessment of symptoms associated with Parkinson’s disease is mainly performed in the
clinic. However, these assessments have limitations because they provide only a snapshot of the condition.
Methods: The feasibility and usability of an objective, continuous and relatively unobtrusive system (SENSE-PARK
System), which consists of wearable sensors (three worn during the day and one worn at night), a smartphone-based
App, a balance board and computer software, was tested 24/7 over 12 weeks in a study including 22 PD patients.
During the first four weeks of the study, patients did not get feedback about their performance, during the last eight
weeks they did. The study included seven clinical visits with standardized interviews, and regular phone contact.
The primary outcome was the number of drop-outs during the study. As secondary outcomes, the Post-Study System
Usability Questionnaire (PSSUQ), score and information obtained from the standardized interviews were used to
evaluate the usability of the system.
Results: All patients completed the study. The participants rated the usability of the SENSE-PARK System with a
mean score of 2.67 (±0.49) on the PSSUQ. The interviews revealed that most participants liked using the system
and appreciated that it signaled changes in their health condition.
Conclusions: This 12 week controlled study demonstrates that the acceptance level of PD patients using the
SENSE-PARK System as a home-based 24/7 assessment is very good. Particular emphasis should be given to a
user-friendly design. Motivation to wear such a system can be increased by providing direct feedback about the
individual health condition.
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At present, measurements of Parkinson’s disease symp-
toms are almost all performed in a clinical setting, which
may not reflect daily life situations. The most widely
used assessment scale for PD symptoms is the Unified
Parkinson’s Disease Rating Scale (MDS - UPDRS) which
includes interviews asking the patient for historical* Correspondence: cgcgodinho@gmail.com
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creativecommons.org/publicdomain/zero/1.0/information referring to the previous week, and a
clinical rating scale which includes semi-quantitative
assessment of motor (dys) function [1]. However, there
is broad agreement in the scientific field that new as-
sessment strategies are needed, in particular those
which have high ecological validity, multiple time
points of evaluation and are effective [2].
Quantitative assessments using wearable technology
may allow for continuous, objective and ecologically
valid data collection and can be applied frequently at
short intervals outside of the physician’s office, allowing
real-time monitoring of symptom changes. This approachrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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therapeutic decisions and ultimately ameliorate patients’
global health status. In addition, such measures have the
potential to be used as outcome parameters in clinical tri-
als, allowing for frequent assessments (e.g., in the home
setting). These wearable sensors are of particular interest
as they can be worn unobtrusively, so they do not rele-
vantly influence the person who wears the sensor during a
test, or during daily life. In addition, they can measure
movements, and can be attached to almost every part of
the body where symptoms of interest can occur [2].
The first studies with such sensors were performed
more than 10 years ago and focused on the assessment
of tremor and dyskinesia. Feeding the information ob-
tained by such sensors back to the individual user, so
that he or she can learn more about the individual dis-
ease presentations and how to counteract disease-
associated symptoms, may provide additional motivation
for users.
Within the framework of an EU-funded project (www-
sense-park.eu), a device consisting of four components:
software, a smartphone app, a Wii balance board and a
set of sensors, was developed [3]. This paper focuses on
the results of this study with regard to feasibility and us-
ability of the SENSE-PARK System over a prolonged
time frame in the home environment of the users.
Methods
A multi-centre, open-label, feasibility and usability study
comprising 22 participants was conducted. Eleven PD
patients were invited to use the SENSE-PARK System
for 12 weeks and perform clinical assessments every
other week. The other 11 patients only completed the
clinical assessments.
The primary outcome was the frequency of drop-outs
and the first secondary outcome was assessed through
the IBM Post-Study Usability Questionnaire (PSSUQ -
rating score from 1, best, to 7, worst).
Technology overview
The SENSE-PARK System consists of a set of wearable
sensors (3 to be used during the day and one at night),
a Wii Balance Board, software and a smartphone app
(Fig. 1).Fig. 1 From left to right: Inertial sensor unit with housing and wristlet banThe sensors monitor movements of PD patients dur-
ing daily activities, collecting motor-related raw data.
Accelerometers and angular rate sensors measure the
motion of the user, and map certain activities. When
awake, the user wears a small sensor at the wrist and the
leg of the more affected side, as well as at the lower back
according to Fig. 1. When asleep, the user wears one
sensor at the lower back only. This set of sensors, together
with algorithms developed during the SENSE-PARK pro-
ject phase, allows monitoring parameters associated with
gait, hypokinesia, dyskinesia, tremor and sleep. Through
the Wii Balance Board, data such as body weight and sway
are also collected. The user also performs cognitive tests
through specific software. These tests use virtual environ-
ments on a screen to evaluate specific cognitive domains,
including alertness, divided attention, response control,
visual exploration and working and topological memory.Staff Training
A two day investigator meeting was conducted to train
staff, including installation of equipment, and procedures
for training participants in the use of the System. Inves-
tigators received training in test administration and
scoring.Participants
A sample of 22 PD patients was divided into two groups:
SENSE-PARK System users and non-users. Inclusion cri-
teria were (1) PD patients between 40 and 85 years of
age, (2) stage 1 to 2.5 (ON) of the Modified Hoehn and
Yahr (H&Y) scale [4] and (3) having experience or inter-
est in technical equipment (computer, regular mouse
and keyboard).
Exclusion criteria included (1) illiteracy, (2) ≤24 in the
Mini Mental State Examination (MMSE) [5], (3) postural
instability item MDS-UPDRS > 2, (4) inability to handle
the device for some other reason.
There were no restrictions on prior and concomitant
therapy. An approval was obtained from the local ethics
committee at the three sites (University of Lisbon,
Portugal; University of Tübingen, Germany; and University
of Tromsö, Norway), and in compliance with national
legislation and Declaration of Helsinki.d; Wii balance board; interface software; SENSE-PARK App
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After signing the informed consent, participants were
screened for eligibility. For the group of users, a home
visit was scheduled to ensure users had the required
home facilities for the use of the SENSE-PARK System
and to install the full system (the mouse setting was de-
fined according to the hand the user normally writes
with). The users were also invited to perform a demo
session, in order to get acquainted with the SENSE-
PARK System. Only balance and cognitive testing had to
be performed “actively”. On cognitive test occasions, pa-
tients were instructed to be seated in a chair in front of
the computer and place the computer and mouse on a
table. Balance tests had to be performed with a Wii Bal-
ance Board which was connected to the local computer
and the SENSE-PARK System. The other domains’ data
were collected with the sensors which were worn
24 hours per day: three to be used during the day and
one at night.
After the installation, participants used the SENSE-
PARK System at home for one week and then they were
observed by the investigator who registered whether the
participants made mistakes during the tasks and whether
they needed assistance. When necessary, another week
of training was allowed. The time needed for confident
SENSE-PARK System operation, test taking, data storage
and data transfer was recorded. As soon as the user was
able to use the SENSE-PARK System adequately and it
was working properly, the assessment phase of the study
started.
During the assessment period, patients who used the
SENSE-PARK System were asked to perform sway as-
sessment and cognitive tests every other day at a similar
time of day during ON stage. Patients selected, in ad-
vance, the days of the week they would perform their
testing, which was then programmed into the SENSE-
PARK System with a reminder coming up on the inter-
face of the software. An ongoing check of data arrival
allowed users who were near to missing their two day win-
dow to be contacted by the study staff. If any problems or
questions developed, users had access to the study staff for
backup support.Fig. 2 Study design. V: Visit; PC: Phone Contact; VH: Home visitsEvery other week during the study, participants from
both groups returned to a health professional expert in
movement disorders or were visited to perform the con-
trol of concomitant medications, check data download,
record the occurrence of any Adverse Event, confirm pa-
tient compliance and to perform the following rating
scales: MDS-UPDRS [1], H&Y [4] , Montreal Cognitive
Assessment (MoCA) [6], Mini–Mental State Examination
(MMSE) [5], Parkinson's Disease Questionnaire-39 (PDQ-
39) [7], EQ-5D [8], Epworth Sleepiness Scale (ESS) [9],
Panic Disorder Severity Scale (PDSS) [10], Non-Motor
Symptoms Scale (NMSS) [11], Unified Dyskinesia Rating
Scale (UdysRS) [12], Clinical Global Impression - Severity
Scale and Improvement Scale (CGI-S and CGI-I) [13].
Between investigator visits, semi-structured interviews
were conducted by phone to gain insight into the experi-
ences of the participants using the SENSE-PARK System.
Topics discussed were: willingness to continue in the
study, satisfaction with the SENSE-PARK System, changes
in health status or medical condition, adverse events, feed-
back messages and doubts about the system. Those partic-
ipants who were not using the SENSE-PARK System were
asked about willingness to continue in the study, health
status, medical condition and adverse events (usability
evaluation).
After 4 weeks of active data collection with the SENSE-
PARK System, the participants received a modified version
of the software. This new version provided feedback to
users (Fig. 2).
At the end of the study period (V8), participants were
asked to fill in the IBM Post-Study Usability Question-
naire (PSSUQ) [14] which assesses user satisfaction with,
and usability of, technical devices. It is a 19-item closed-
ended ordinal questionnaire, based on 7-point graphic
Likert scales. The items address five important compo-
nents of user satisfaction with general computer systems
usability: ease of use, ease of learning, simplicity, effect-
iveness, information, and the user interface [15].
Statistical analysis
Statistical analyses were performed in R, version 3.0.3.
Subject demographic and clinical data were examined by
Table 1 Baseline Characteristics
Germany Norway Portugal p-
valueUser Non-User User Non-User User Non-User
Nr or participants (male) 5 (3) 5 (3) 3 (0) 3 (2) 3 (3) 3 (3) 0.09
Age (mean ± sd) 60.2 (9.8) 60.6 (10.5) 59.3 (3.7) 53 (9.9) 66 (2.7) 60 (6.2) 0.37
HY (median, range) 2 (2–3) 1.5 (1–1.5) 2 (2–2) 1 (1–2) 2 (1–2) 2 (2–2) 1.00
Total MDS-UPDRS (median, range) 61 (53–76) 61 (49–45) 52 (46–56) 26 (22–31) 50 (26–65) 60 (45–70) 0.23
MDS-UPDRS part III (median, range) 40 (28–42) 17 (11–29) 17 (16–24) 15 (10–15) 26 (15–37) 40 (38–44) 0.05
Total MMSE (median,range) 30 (29–30) 29 (29–30) 29 (29–30) 30 (29–30) 29 (29–30) 28 (26–30) 0.60
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users and was tested with the PSSUQ values obtained at
the end of the study (see above). Feasibility was assessed
for users and non-users. For non-users, feasibility was
assessed through willingness to continue in the study
and through completeness of the study, i.e. withdrawals
from the study. For users, feasibility was assessed through
the following indices: willingness to continue in the study
and through completeness of the study, duration of time
to train participants to use the SENSE-PARK SystemFig. 3 a Bar plot showing the frequency of doubts along the study; b Num
recorded dataconfidently, compliance in terms of the number of com-
pleted test sessions and their timeliness with every other
day assessments, compliance/adherence to system mea-
sures, success of data transfer and decryption, ease of use
and program satisfaction [16, 17].
Results
Twenty two idiopathic PD patients (14 male, 8 female)
were included in the study (Table 1). There were no sig-
nificant differences regarding age and sex distribution asber of tasks preformed; c Number of times the investigator found the
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not significantly different, study participants included in
Norway were slightly younger.
Feasibility aspects
Users
All participants showed willingness to continue in the
study from visit 1 to visit 8, and all of them completed
the study. Most participants completed the tasks asked
for during the study and according to the protocol.
Number of doubts and difficulties decreased along the
study (Fig. 3). Only one participant failed to transfer the
data when asked. All the other SENSE-PARK System
users were able to download the data along the study.
Non-users
All participants showed willingness to continue in the
study from visit 1 to visit 8, and all of them completed
the study. Since these patients were not system users
questions concerning data transfer, number of doubts and
difficulties and completion of tasks were not assessed.
No adverse events were recorded.
Usability aspects
Usability aspects were only assessed for system users.
Overall analyses from the PSSUQ scale showed that the
system was generally well accepted (Fig. 4). Analysis of the
PSSUQ scale by country showed that study participantsFig. 4 Plot showing the mean values of responses for the PSSUQ scale divfrom Norway had a slightly different profile than those
from the other countries, scoring less (i.e. better) with
regard to system use in items such as ability to efficiently
complete tasks, comfort with using the system, and ease
of learning.
Problems that arise from using this device
There were four adverse events registered, three of them
being classified as definitely related to the study and one
being possibly related to the study (Table 2).
Discussion
We found the SENSE-PARK System highly feasible in
terms of patient compliance, satisfaction and ease of use.
Patients maintained their involvement with the program
over 16 weeks, and several requested a continuation of
the program at study end. We were initially concerned
that participants would find the testing process, of every
other day participation and weekly visits, tedious, but
the satisfaction ratings did not support this concern, and
the computer-based technology guided the test-taking
smoothly. However, we encountered more problems with
transmission and sensor errors compared to other tasks,
but by mid-study, technical correction was achieved.
Hardware related problems consisted mainly of a broken
sensor. Battery replacements were not required.
The training period was short and the testing was
self-administered without direct investigator involvement.ided by country
Table 2 Adverse events description
Adverse Events
Group Number of cases Country Description
User 2 cases Portugal Allergy to plastic bracelet
Loss of wrist sensor
1 case Norway Minor stroke
1 case Germany Broken sensor
Non-user No adverse events were reported
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as a monitoring tool, after the first 4 weeks we allowed
users to see their previous scores when they took their
next test.
Conclusions
This pilot study is a “proof of concept” and establishes pa-
tient and technical feasibility of the SENSE-PARK system.
There is, as yet, no evidence that using this test array
will improve treatment of patients during clinical prac-
tice or that a cost benefit analysis is favorable. Further
studies are needed to test how the test array performs in
a clinical setting with larger patient populations. One
question to be addressed is whether the SENSE-PARK
System can detect a need for treatment changes. Additionally,
whether there are country-specific issues, creating different re-
quirements for its introduction into clinical practice, needs to
be evaluated.
Abbreviations
CGI-I: Clinical global impression - Improvement scale; CGI-S: Clinical global
impression - Severity scale; EQ-5D: EuroQol-5D; ESS: Epworth sleepiness scale;
H&Y: Hoehn and Yahr; MDS-UPDRS: (Movement disorder society) Unified
Parkinson’s disease rating scale; MMSE: Mini–mental state examination;
MoCA: Montreal cognitive assessment; NMSS: Non-motor symptoms scale
PDQ-39, Parkinson's disease questionnaire-39; PDSS: Panic disorder severity
scale; PSSUQ: Post-study system usability questionnaire; UdysRS: Unified
Dyskinesia rating scale.
Competing interests
Joaquim J. Ferreira has held consultancy functions with GlaxoSmithKline,
Novartis, TEVA, Lundbeck, Solvay, Abbott, BIAL, Merck-Serono, Merz, Ipsen;
has received grants from GlaxoSmithKline, Grunenthal, Fundação MSD
(Portugal) and Teva; has been a member of the European Huntington Disease
Network and has been employed by Centro Hospitalar Lisboa Norte, Faculdade
de Medicina de Lisboa. Helen Matthews has been employed byThe Cure
Parkinson’s Trust. Walter Maetzler has received speaker honoraria from
UCB, GlaxoSmithKline and Rölke Pharma. None of the other authors have
any competing interests to report.
Authors’ contributions
JJF: conception and design, revising it critically for important intellectual
content, has given final approval of the version to be published. ATS: conception
and design, drafting the manuscript, has given final approval of the version to
be published. CG: acquisition of data, drafting the manuscript, has given final
approval of the version to be published. JD: conception and design, drafting
the manuscript, has given final approval of the version to be published.
DA: analysis and interpretation of data, drafting the manuscript, has given final
approval of the version to be published. NG: analysis and interpretation of data,
drafting the manuscript, has given final approval of the version to be published.
MB: analysis and interpretation of data, drafting the manuscript, has given final
approval of the version to be published. FL: conception and design, drafting themanuscript, has given final approval of the version to be published. IA: acquisition
of data, drafting the manuscript, has given final approval of the version to be
published. HW: acquisition of data, drafting the manuscript, has given final
approval of the version to be published. AS: conception and design, drafting
the manuscript, has given final approval of the version to be published.
PW: conception and design, drafting the manuscript, has given final approval of
the version to be published. AT: conception and design, drafting the manuscript,
has given final approval of the version to be published. SM: conception and
design, drafting the manuscript, has given final approval of the version to be
published. SS: conception and design, drafting the manuscript, has given final
approval of the version to be published. JU: acquisition of data, drafting the
manuscript, has given final approval of the version to be published.
MAH: acquisition of data, drafting the manuscript, has given final approval of
the version to be published. KSM: acquisition of data, drafting the manuscript,
has given final approval of the version to be published. HM: conception and
design, drafting the manuscript, has given final approval of the version to be
published. TI: conception and design, drafting the manuscript, has given final
approval of the version to be published. JD: conception and design, drafting
the manuscript, has given final approval of the version to be published. HG:
conception and design, revising it critically for important intellectual content,
has given final approval of the version to be published. WM: conception and
design, revising it critically for important intellectual content, has given final
approval of the version to be published. All authors agree to be accountable
for all aspects of the work in ensuring that questions related to the accuracy
or integrity of any part of the work are appropriately investigated and resolved.
Acknowledgements
This study was performed in the frame of the EU project SENSE-PARK,
funded under the Seventh Framework Programme, Cooperation – ICT,
Grant Agreement no. 288557.
Author details
1Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal.
2Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine,
University of Lisbon, Lisbon, Portugal. 3CNS – Campus Neurológico Sénior,
Torres Vedras, Portugal. 4Center for Interdisciplinary Research Egas Moniz
(CiiEM), Cooperativa de Ensino Superior Egas Moniz, Monte de Caparica,
Caparica, Portugal. 5NST-Norwegian Centre for Integrated Care and
Telemedicine, University Hospital North Norway, Tromsø, Norway. 6Department
of Clinical Medicine, Faculty of Health Sciences, The Arctic University of Norway,
Tromsø, Norway. 7Hasomed GmbH, Magdeburg, Germany. 8HSG-IMIT,
Villingen-Schwenningen, Germany. 9AbilityNet, London, UK. 10Hertie Institute for
Clinical Brain Research, Department of Neurodegeneration, Center of Neurology,
University of Tuebingen, Tuebingen, Germany. 11DZNE, German Center for
Neurodegenerative Diseases, Tübingen, Germany. 12The Cure Parkinson’s Trust,
London, UK. 13Institute for Medical Genetics and Applied Genomics, University
of Tübingen, Tuebingen, Germany.
Received: 27 November 2014 Accepted: 20 May 2015
References
1. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT,
et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's
Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.
Mov Disord. 2007;22:41–7.
2. Maetzler W, Domingos J, Srulijes K, Ferreira JJ, Bloem BR. Quantitative
wearable sensors for objective assessment of Parkinson's disease.
Mov Disord. 2013;28:1628–37.
3. Serrano JA, Thoms A, Weber P. Patients Initiated Timeline Marking of Events
in Parkinson’s Disease: Visualization of Time Correlation between Patients
Marked Events and Acquired Data from Sensors. In: Schmorrow D,
Fidopiastis C, editors. Foundations of Augmented Cognition Advancing
Human Performance and Decision-Making through Adaptive Systems.
Lecture Notes in Computer Science. Springer International Publishing.
2014;8534:325-34.
4. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality.
Neurology. 1967;17:427–42.
5. Pangman VC, Sloan J, Guse L. An examination of psychometric properties of
the mini-mental state examination and the standardized mini-mental state
examination: implications for clinical practice. ANR. 2000;13:209–13.
Ferreira et al. BMC Neurology  (2015) 15:89 Page 7 of 76. Gill DJ, Freshman A, Blender JA, Ravina B. The Montreal cognitive
assessment as a screening tool for cognitive impairment in Parkinson's
disease. Mov Disord. 2008;23:1043–6.
7. Jenkinson C, Peto V, Fitzpatrick R, Greenhall R, Hyman N. Self-reported
functioning and well-being in patients with Parkinson's disease: comparison
of the short-form health survey (SF-36) and the Parkinson's Disease
Questionnaire (PDQ-39). Age Ageing. 1995;24:505–9.
8. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol
Group. Ann Med. 2001;33:337–43.
9. Johns MW. A new method for measuring daytime sleepiness: the Epworth
sleepiness scale. Sleep. 1991;14:540–5.
10. Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, et al.
Multicenter collaborative panic disorder severity scale. J Psychiatry.
1997;154:1571–5.
11. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, et al.
The metric properties of a novel non-motor symptoms scale for Parkinson's
disease: Results from an international pilot study. Mov Disord. 2007;22:1901–11.
12. Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale:
presentation and clinimetric profile. Mov Disord. 2008;23:2398–403.
13. Guy., William. ECDEU assessment manual for psychopharmacology Rockville,
Md.: U.S. Dept. of Health, Education, and Welfare, Public Health Service,
Alcohol, Drug Abuse, and Mental Health Administration, National Institute
of Mental Health, Psychopharmacology Research Branch, Division of
Extramural Research Programs. Maryland, US: U.S. Dept. of Health 1976.
14. Fruhling A, Lee S. Assessing the Reliability, Validity and Adaptability of
PSSUQ. AMCIS 2005 Proceedings 2005.
15. Lewis JR. IBM computer usability satisfaction questionnaires: psychometric
evaluation and instructions for use. Int J Hum-Comput Interact. 1995;7:57–78.
16. Parsons A, McCullough C, Wang J, Shih S. Validity of electronic health
record-derived quality measurement for performance monitoring. Journal of
the American Medical Informatics Association 2012;19(4):604–9.
17. Bowen DJ, Kreuter M, Spring B, Cofta-Woerpel L, Linnan L, Weiner D, et al.
How we design feasibility studies. Am J Prev Med. 2009;36:452–7.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
